Product Description

SlimAssist is a dual-component research compound formulated for in vitro and preclinical studies examining skeletal muscle preservation under conditions of concurrent metabolic intervention.

Each research vial contains two precisely characterized components.

Component 1 — FLGR242 (2mg)

FLGR242 is a fragmented, modified version of Follistatin-344 developed via recombinant technology. It selectively binds and inhibits myostatin activity without the off-target activin interactions typically observed with standard follistatin analogs in laboratory models.

A patented albumin-binding construct confers high-affinity serum albumin binding (Kd <20 nM), extending the compound’s serum persistence period to approximately 19 days. This extended serum residence makes FLGR242 well-suited for long-interval experimental protocols without compromising binding selectivity.

Component 2 — Vitamin B Complex (500mcg)

A research-grade B6, and B12 complex with Vitamin B6 as the primary constituent. This complex supports cofactor-dependent pathways in cellular energy metabolism and mitochondrial function models, including transaminase activity and NAD+ precursor availability in cell culture systems.

Together, these components are designed to support preclinical research protocols examining skeletal muscle preservation in models where accelerated muscle catabolism is observed alongside concurrent GLP-1 receptor agonist compound application.

US GMP-manufactured with triple third-party verification and comprehensive COAs for reproducible research outcomes.

Compound Information

---

Lyophilized Peptides

These compounds are freeze-dried, a process that preserves purity and molecular integrity during storage. No fillers or additives are used in this process.

SlimAssist Research

SlimAssist combines two research-relevant components targeting complementary pathways in skeletal muscle catabolism and metabolic cofactor activity. The following summarizes supporting literature across both components.

Myostatin Inhibition and Skeletal Muscle Fiber Research

Myostatin (GDF-8) is a TGF-β superfamily member that suppresses muscle fiber development by activating SMAD2/3 signaling cascades. In laboratory models, elevated myostatin expression correlates with accelerated skeletal muscle catabolism during energy restriction and caloric deficit states [1].

Standard follistatin analogs bind both myostatin and activin, producing off-target cellular growth effects that complicate experimental interpretation. FLGR242 addresses this limitation by selectively inhibiting myostatin without co-inhibiting activin — yielding cleaner experimental protocols for TGF-β pathway research [2].

Research in laboratory models demonstrates that follistatin-based myostatin inhibition increases muscle fiber cross-sectional area and supports satellite cell activation in regeneration assays [3].

Albumin-Binding Construct and Extended Serum Persistence

The patented albumin-binding construct in FLGR242 uses a hydrophilic glycine-serine linker to achieve high-affinity binding to serum albumin (Kd <20 nM). This extends the compound’s serum persistence period to approximately 19 days.

Albumin-fusion strategies represent a validated approach in recombinant protein research for extending serum residence without altering primary biological activity [4]. This characteristic is particularly relevant for researchers designing multi-week experimental timelines with reduced compound application intervals.

Skeletal Muscle Preservation in GLP-1 Receptor Agonist Research Models

Translational and preclinical research models have identified accelerated lean mass reduction as a notable observation in study subjects alongside GLP-1 receptor agonist compound application combined with caloric restriction protocols [5].

Myostatin pathway modulation has been proposed as a contributing mechanism in these models. Research examining concomitant selective myostatin inhibition and GLP-1 pathway activity represents an active investigative area for researchers studying body composition dynamics under metabolic intervention conditions.

The selectivity and extended serum persistence period of FLGR242 position it as a candidate research tool for these protocol designs.

Vitamin B6 and Enzymatic Cofactor Activity

Vitamin B6 (pyridoxine) serves as an essential cofactor for more than 100 enzymatic reactions in cellular metabolism, including aminotransferases central to amino acid catabolism and gluconeogenesis pathways in cell line models [6].

In metabolic research models, sufficient B6 availability supports mitochondrial energy production and intracellular energy flux under conditions of substrate restriction [7]. These properties make B6 a relevant component in protocols examining cellular metabolic resilience alongside skeletal muscle preservation pathways.

Vitamin B3 and NAD+ Pathway Research

Niacin (Vitamin B3) is a biosynthetic precursor to NAD+ and NADP+ — coenzymes governing cellular redox reactions and mitochondrial respiration across mammalian cell types [8].

In vitro studies demonstrate that B3 availability supports NAD+ pool maintenance under conditions of increased metabolic demand. This cofactor role positions B3 as a relevant variable in protocols examining energy homeostasis alongside muscle catabolism research.

Vitamin B12 and Amino Acid Metabolism

Vitamin B12 (cobalamin) functions as a cofactor for methionine synthase and methylmalonyl-CoA mutase — enzymes central to amino acid and fatty acid metabolism in mammalian cell culture systems [9].

B12 activity in cellular models supports protein biosynthesis pathways relevant to skeletal muscle research protocols, particularly those examining anabolic signaling alongside myostatin inhibition.

In Vitro Research Applications

Certificate of Analysis (COA) for Every Batch

A Certificate of Analysis (COA) is a document that verifies a compound’s identity, purity, and batch quality through independent laboratory testing. Every compound from BioLongevity Labs ships with a COA tied to its specific batch, so researchers can confirm exactly what they received before it enters a protocol.

Each COA reports results from third-party laboratory analysis, including:

• High-performance liquid chromatography (HPLC) for purity, typically confirmed at 99% or higher
• Liquid chromatography mass spectrometry (LC-MS) for molecular identity and mass confirmation
• Sterility and endotoxin screening where applicable
• Chemical contaminant and residual solvent checks

COAs are sourced from independent certified labs rather than in-house testing alone, giving researchers a verifiable record of molecular integrity for each batch. All compounds are supplied for research use only.